title: Identification of undiagnosed inflammatory arthritis in a community health fair screen.
abstract: OBJECTIVE
  To identify individuals with undiagnosed inflammatory arthritis (IA) and rheumatoid arthritis (RA) in a community health fair screen, and to establish in a health fair setting the diagnostic accuracy of combinations of the Connective Tissue Disease Screening Questionnaire (CSQ) and autoantibody testing for IA.
  
  
  METHODS
  Screening for IA/RA was performed at health fair sites using a combination of the CSQ, joint examination, rheumatoid factor, and anti-cyclic citrullinated peptide (anti-CCP) antibody testing. IA was defined as > or =1 swollen joint suggestive of synovitis on joint examination by a trained clinician.
  
  
  RESULTS
  Six hundred one subjects were screened; 51.0% participated because of joint symptoms (pain, stiffness, or swelling). Eighty-four subjects (14.0%) had > or =1 swollen joint, designated as IA on joint examination. Of the 601 subjects screened, 9 (1.5%) had IA and met > or =4 of 7 American College of Rheumatology criteria for RA but had no prior diagnosis of RA, and 15 (2.5%) had IA and RF and/or anti-CCP positivity, suggesting early RA. The diagnostic accuracy of combinations of the CSQ and autoantibody testing for the identification of IA yielded maximal sensitivity, specificity, and positive and negative predictive values of 95.3%, 99.2%, 71.4%, and 97.7%, respectively.
  
  
  CONCLUSIONS
  Health fair screening may be an effective approach for the identification of individuals with undiagnosed IA/RA. A combination of the CSQ and autoantibody testing alone has clinically useful diagnostic accuracy for the detection of IA. Decisions regarding which methodology to use for future health fair IA/RA screening will depend on goals of screening and funding.
authors: University of Colorado Denver, Aurora, CO, USA. Kevin.Deane@UCDenver.edu
authors: Kevin D
authors: KD
authors: Deane
authors: Christopher C
authors: CC
authors: Striebich
authors: Barbara L
authors: BL
authors: Goldstein
authors: Lezlie A
authors: LA
authors: Derber
authors: Mark C
authors: MC
authors: Parish
authors: Marie L
authors: ML
authors: Feser
authors: Elaine M
authors: EM
authors: Hamburger
authors: Stacey
authors: S
authors: Brake
authors: Cindy
authors: C
authors: Belz
authors: James
authors: J
authors: Goddard
authors: Jill M
authors: JM
authors: Norris
authors: Elizabeth W
authors: EW
authors: Karlson
authors: V Michael
authors: VM
authors: Holers
mesh_terms: D001172:Arthritis, Rheumatoid / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D003120:Colorado / Q000453:epidemiology; D003159:Community-Institutional Relations; D042241:Early Diagnosis; D005260:Female; D006277:Health Fairs; D006801:Humans; D007596:Joints / Q000473:pathology; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000097:blood / Q000276:immunology; D015203:Reproducibility of Results; D012217:Rheumatoid Factor / Q000097:blood; D016036:Seroepidemiologic Studies; D011795:Surveys and Questionnaires; D013585:Synovitis / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; D010456:Peptides, Cyclic; C487763:cyclic citrullinated peptide; D012217:Rheumatoid Factor